Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a global pharmaceutical company specializing in the development, manufacturing and marketing of generic and specialty-branded products. Headquartered in Bridgewater, New Jersey, the company offers a broad portfolio that spans oral solid, oral liquid, injectable and transdermal dosage forms. In addition to finished dosage forms, Amneal produces active pharmaceutical ingredients (APIs) at manufacturing facilities in the United States, India and Canada, supporting both its own product pipeline and third-party customers.
Since its founding in 2002 by brothers Chirag and Chintu Patel, Amneal has pursued a strategy of growth through internal research and development as well as strategic acquisitions. A landmark transaction in 2018 merged Amneal with Impax Laboratories, expanding its specialty product offerings and strengthening its presence in neurology and endocrinology. The combination of in-house R&D, manufacturing scale and a diversified product mix has positioned the company to launch complex generics and biosimilars alongside more established generic medicines.
Amneal’s international reach extends across North America, Europe and select emerging markets. In the United States, the company markets hundreds of generic pharmaceuticals and holds abbreviated new drug applications (ANDAs) with the U.S. Food and Drug Administration. Its India operations include API production and the domestic marketing of both generic and specialty brands. Amneal is also pursuing dossiers for regulated markets in Europe and other regions, leveraging partnerships and distribution alliances to broaden patient access to affordable therapies.
Under the leadership of Co-Chief Executive Officers Chirag Patel and Chintu Patel, Amneal continues to balance investment in new product development with operational efficiencies. The company maintains a robust pipeline targeting respiratory, autoimmune, oncology and neurology therapies, while exploring next-generation delivery technologies. With a diversified platform spanning generics, specialty branded pharmaceuticals and biosimilars, Amneal Pharmaceuticals aims to address evolving healthcare needs through cost-effective, high-quality medicines.
AI Generated. May Contain Errors.
